Disappearance of cerebrospinal fluid oligoclonal bands after natalizumab treatment of multiple sclerosis patients

Multiple Sclerosis Journal

Volumn 18, Issue 7, 2012, Pages 1038-1041

  Von Glehn, Felipe ^a   Farias, Alessandro S ^a   De Oliveira, Augusto C Penalva ^a   Damasceno, Alfredo ^a   Longhini, Ana Leda F ^a   Oliveira, Elaine C ^a   Damasceno, Benito P ^a   Santos, Leonilda M B ^a   Brandão, Carlos Otávio ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

cerebrospinal fluid; multiple sclerosis; natalizumab therapy; oligoclonal bands

Indexed keywords

IMMUNOGLOBULIN G; NATALIZUMAB; OLIGOCLONAL BAND;

ADULT; ARTICLE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; FEMALE; HUMAN; LUMBAR PUNCTURE; MALE; MULTIPLE SCLEROSIS; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL;

EID: 84863224814     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458511428465     Document Type: Article

References (11)

1. Ramagopalan SV, Dobson R, Meier UC and Giovannoni G. Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurol 2010; 9: 727-739.
2. Antel J and Bar-Or A. Roles of immunoglobulins and B cells in multiple sclerosis: from pathogenesis to treatment. J Neuroimmunol 2006; 180: 3-8.
3. Freedman MS, Thompson EJ, Deisenhammer F, Giovannoni G, Grimsley G, Keir G, et al. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis. Arch Neurol 2005; 62: 865-870.
4. Correale J and Molinas MMB. Oligoclonal bands and antibody responses in multiple sclerosis. J Neurol 2002; 249: 375-389.
5. Rudick RA, Cookfair DL, Simonian NA, Ransohoff RM, Richert JR, Jacobs LD, et al. Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. J Neuroimmunol 1999; 93: 8-14. (Pubitemid 29051546)
6. Saiz A, Carreras E, Berenguer J, Yagüe J, Martínez C, Marín P, et al. MRI and CSF oligoclonal bands after autologous hematopoietic stem cell transplantation in MS. Neurology 2001; 56: 1084-1089.
7. Piccio L, Naismith RT, Trinkaus K, Klein RS, Parks BJ, Lyons JA, et al. Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch Neurol 2010; 67: 707-714.
8. Niino M, Bodner C, Simard ML, Alatab S, Gano D, Kim HJ, et al. Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol 2006; 59: 748-754.
9. Damasceno A, von Glehn F, Martinez A, Longhini A, Deus-Silva L, Brandão C, et al. Early onset of natalizumab-related progressive multifocal leukoencephalopathy. Mult Scler 2011; 00: 1-3 (accessed 07 September 2011).
10. Reiber H, Ungefehr S and Jacobi C. The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis. Mult Scler 1998; 4: 111-117. (Pubitemid 28410034)
11. Knowles WA, Luxton RW, Hand JF, Gardner SD and Brown DWG. The JC virus antibody response in serum and cerebrospinal fluid in progressive multifocal leukoencephalopathy. Clin Diagn Virol 1995; 2: 183-194.